Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

被引：0
|
作者：
Ignacio Bernabéu
Carmen Fajardo
Mónica Marazuela
Fernando Cordido
Eva María Venegas
Pedro de Pablos-Velasco
Gonzalo Piedrola Maroto
María Pilar Olvera
Isabel Pavón de Paz
Davide Carvalho
Carme Romero
Guillermo De la Cruz
Cristina Álvarez Escolá
机构：
[1] Hospital Clínico Universitario Santiago de Compostela,Endocrinology and Nutrition Department
[2] Hospital Universitario de La Ribera,Endocrinology and Nutrition Department
[3] Hospital Universitario La Princesa,Endocrinology and Nutrition Department
[4] Universidad Autónoma Madrid,Faculty of Health Sciences and INIBIC, University of A Coruña, and Endocrinology and Nutrition Department
[5] Instituto Princesa,Endocrinology and Nutrition Department
[6] Complejo Hospitalario Universitario de A Coruña,Endocrinology and Nutrition Department
[7] Hospital Universitario Virgen del Rocío,Department of Endocrinology, Diabetes and Metabolism, Centro Hospitalar Universitário São João
[8] University of Las Palmas de Gran Canaria. Spain,Endocrinology and Nutrition Department
[9] Endocrinology and Nutrition Departament Hospital Universitario Virgen de las Nieves,undefined
[10] Endocrinology and Nutrition Departament,undefined
[11] Hospital Universitario Nuestra Señora de Candelaria,undefined
[12] Endocrinology and Nutrition Departament,undefined
[13] Hospital Universitario de Getafe,undefined
[14] Faculty of Medicine,undefined
[15] i3S,undefined
[16] Universidade do Porto,undefined
[17] Adknoma Health Research S.L.,undefined
[18] Ipsen Pharma,undefined
[19] Hospital Universitario La Paz,undefined
来源：
Endocrine | 2020年 / 70卷
关键词：
Acromegaly; Lanreotide; Insulin-like growth factor 1; Somatostatin; Growth hormone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：575 / 583
页数：8
相关论文
共 50 条
  • [21] Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study
    Bolanowski, Marek
    Hubalewska-Dydejczyk, Alicja
    Kos-Kudla, Beata
    Ruchala, Marek
    Witek, Przemyslaw
    Zgliczynski, Wojciech
    Houchard, Aude
    Bartmanska, Marta
    ENDOKRYNOLOGIA POLSKA, 2021, 72 (05) : 512 - 519
  • [22] A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly
    M. Fleseriu
    Z. Zhang
    K. Hanman
    K. Haria
    A. Houchard
    S. Khawaja
    A. Ribeiro-Oliveira
    M. Gadelha
    Pituitary, 2023, 26 : 9 - 41
  • [23] Dosage and costs of lanreotide Autogel 120 mg administered as part of routine acromegaly care in Poland - two years of data from Lanro-Study
    Orlewska, Ewa
    Kos-Kudla, Beata
    Sowinski, Jerzy
    Sworczak, Krzysztof
    Zgliczynski, Wojciech
    ENDOKRYNOLOGIA POLSKA, 2015, 66 (02) : 142 - 148
  • [24] A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly
    Fleseriu, M.
    Zhang, Z.
    Hanman, K.
    Haria, K.
    Houchard, A.
    Khawaja, S.
    Ribeiro-Oliveira, A., Jr.
    Gadelha, M.
    PITUITARY, 2023, 26 (01) : 9 - 41
  • [25] Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism
    Shimatsu, Akira
    Teramoto, Akira
    Hizuka, Naomi
    Kitai, Kazuo
    Ramis, Joaquim
    Chihara, Kazuo
    ENDOCRINE JOURNAL, 2013, 60 (05) : 651 - 663
  • [26] Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
    Yasemin Tutuncu
    Dilek Berker
    Serhat Isik
    Ufuk Ozuguz
    Gulhan Akbaba
    Ferit Kerim Kucukler
    Yusuf Aydin
    Serdar Guler
    Pituitary, 2012, 15 : 398 - 404
  • [27] Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly
    G. Lombardi
    F. Minuto
    G. Tamburrano
    M. R. Ambrosio
    G. Arnaldi
    M. Arosio
    V. Chiarini
    R. Cozzi
    S. Grottoli
    F. Mantero
    F. Bogazzi
    M. Terzolo
    P. Tita
    P. F. Boscani
    A. Colao
    Journal of Endocrinological Investigation, 2009, 32 : 202 - 209
  • [28] Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)
    An, Zhenmei
    Lei, Ting
    Duan, Lian
    Hu, Pei
    Gou, Zhongping
    Zhang, Lihui
    Durand-Gasselin, Lucie
    Wang, Nan
    Wang, Yan
    Gu, Feng
    BMC ENDOCRINE DISORDERS, 2020, 20 (01)
  • [29] Sustained biochemical control in patients with acromegaly treated with lanreotide depot 120 mg administered every 4 weeks, or an extended dosing interval of 6 or 8 weeks: a pharmacokinetic approach
    Gomez-Panzani, Edda
    Chang, Stephen
    Ramis, Joaquim
    Landolfi, Michelle M.
    Bakker, Bert
    RESEARCH AND REPORTS IN ENDOCRINE DISORDERS, 2012, 2 : 79 - 84
  • [30] Efficacy of lanreotide 120 mg primary therapy on tumour shrinkage and ophthalmologic symptoms in acromegaly after 1 month
    Benderradji, Hamza
    Vernotte, Elise
    Ares, Gustave Soto
    Woillez, Jean Philippe
    Jannin, Arnaud
    Perbet, Romain
    Karnoub, Melodie-Anne
    Soudan, Benoit
    Assaker, Richard
    Buee, Luc
    Prevot, Vincent
    Maurage, Claude-Alain
    Pigny, Pascal
    Vantyghem, Marie-Christine
    Merlen, Emilie
    Cortet, Christine
    CLINICAL ENDOCRINOLOGY, 2022, 97 (01) : 52 - 63
12345